Cargando…
Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis
BACKGROUND: Methicillin resistant Staphylococcus aureus (MRSA) is the leading pathogenic cause of nosocomial infections, especially in bacteraemia and sepsis. The essential therapy for MRSA infection is glycopeptides. Therapeutic failure can be seen with this therapy and the mortality is still high....
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526191/ https://www.ncbi.nlm.nih.gov/pubmed/15491501 http://dx.doi.org/10.1186/1471-2334-4-43 |
_version_ | 1782121924088823808 |
---|---|
author | Alp, Emine Gozukucuk, Suveyda Canoz, Ozlem Kirmaci, Beyhan Doganay, Mehmet |
author_facet | Alp, Emine Gozukucuk, Suveyda Canoz, Ozlem Kirmaci, Beyhan Doganay, Mehmet |
author_sort | Alp, Emine |
collection | PubMed |
description | BACKGROUND: Methicillin resistant Staphylococcus aureus (MRSA) is the leading pathogenic cause of nosocomial infections, especially in bacteraemia and sepsis. The essential therapy for MRSA infection is glycopeptides. Therapeutic failure can be seen with this therapy and the mortality is still high. The aim of this study was to evaluate the additional effect of G-CSF on the traditional antibiotic treatment in an experimental MRSA sepsis. METHODS: Experimental sepsis was performed in mice by intraperitoneal injection of MRSA isolate. Inoculum dose was estimated as 6 × 10(9)/ml. Mice were randomised for the study into four group; control group (not receive any therapy), G-CSF group (1000 ng/daily, subcutaneously for 3 d), antibiotic group (vancomycin 25 or 50 mg/kg intraperitoneally every 12 hours for 7 d), and vancomycin+G-CSF group (at the same concentrations and duration). Autopsy was done within one hour after mice died. If mice was still alive at the end of seventh day, they were sacrificed, and autopsy was done. In all groups, the effect of G-CSF therapy on the survival, the number of the MRSA colonies in the lung, liver, heart, spleen, and peritoneal cultures, the histopathology of the lung, liver, heart and spleen was investigated. RESULTS: One hundred and six mice were used. There were no significant differences in survival rates and bacterial eradication in G-CSF group compared with control group, and also in antibiotic +G-CSF group compared with antibiotic alone group. These parameters were all significantly different in antibiotic alone group compared with control group. Histopathologically, inflammation of the lung and liver were significantly reduced in vancomycin (25 mg/kg)+G-CSF and vancomycin (50 mg/kg)+G-CSF subgroups, respectively (p < 0.01). The histopathological inflammation of the other organs was not significantly different in antibiotic+G-CSF group compared with antibiotic group and, also G-CSF group compared with control group. CONCLUSION: G-CSF treatment had no additional effect on survival and bacterial eradication in MRSA sepsis in nonneutropenic mice; and only a little effect on histopathology. G-CSF treatment is very expensive, likewise glycopeptides. The more interest in infection control measures, and prevent the spread of MRSA infections is more rational. |
format | Text |
id | pubmed-526191 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-5261912004-11-10 Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis Alp, Emine Gozukucuk, Suveyda Canoz, Ozlem Kirmaci, Beyhan Doganay, Mehmet BMC Infect Dis Research Article BACKGROUND: Methicillin resistant Staphylococcus aureus (MRSA) is the leading pathogenic cause of nosocomial infections, especially in bacteraemia and sepsis. The essential therapy for MRSA infection is glycopeptides. Therapeutic failure can be seen with this therapy and the mortality is still high. The aim of this study was to evaluate the additional effect of G-CSF on the traditional antibiotic treatment in an experimental MRSA sepsis. METHODS: Experimental sepsis was performed in mice by intraperitoneal injection of MRSA isolate. Inoculum dose was estimated as 6 × 10(9)/ml. Mice were randomised for the study into four group; control group (not receive any therapy), G-CSF group (1000 ng/daily, subcutaneously for 3 d), antibiotic group (vancomycin 25 or 50 mg/kg intraperitoneally every 12 hours for 7 d), and vancomycin+G-CSF group (at the same concentrations and duration). Autopsy was done within one hour after mice died. If mice was still alive at the end of seventh day, they were sacrificed, and autopsy was done. In all groups, the effect of G-CSF therapy on the survival, the number of the MRSA colonies in the lung, liver, heart, spleen, and peritoneal cultures, the histopathology of the lung, liver, heart and spleen was investigated. RESULTS: One hundred and six mice were used. There were no significant differences in survival rates and bacterial eradication in G-CSF group compared with control group, and also in antibiotic +G-CSF group compared with antibiotic alone group. These parameters were all significantly different in antibiotic alone group compared with control group. Histopathologically, inflammation of the lung and liver were significantly reduced in vancomycin (25 mg/kg)+G-CSF and vancomycin (50 mg/kg)+G-CSF subgroups, respectively (p < 0.01). The histopathological inflammation of the other organs was not significantly different in antibiotic+G-CSF group compared with antibiotic group and, also G-CSF group compared with control group. CONCLUSION: G-CSF treatment had no additional effect on survival and bacterial eradication in MRSA sepsis in nonneutropenic mice; and only a little effect on histopathology. G-CSF treatment is very expensive, likewise glycopeptides. The more interest in infection control measures, and prevent the spread of MRSA infections is more rational. BioMed Central 2004-10-18 /pmc/articles/PMC526191/ /pubmed/15491501 http://dx.doi.org/10.1186/1471-2334-4-43 Text en Copyright © 2004 Alp et al; licensee BioMed Central Ltd. |
spellingShingle | Research Article Alp, Emine Gozukucuk, Suveyda Canoz, Ozlem Kirmaci, Beyhan Doganay, Mehmet Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis |
title | Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis |
title_full | Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis |
title_fullStr | Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis |
title_full_unstemmed | Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis |
title_short | Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis |
title_sort | effect of granulocyte colony-stimulating factor in experimental methicillin resistant staphylococcus aureus sepsis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526191/ https://www.ncbi.nlm.nih.gov/pubmed/15491501 http://dx.doi.org/10.1186/1471-2334-4-43 |
work_keys_str_mv | AT alpemine effectofgranulocytecolonystimulatingfactorinexperimentalmethicillinresistantstaphylococcusaureussepsis AT gozukucuksuveyda effectofgranulocytecolonystimulatingfactorinexperimentalmethicillinresistantstaphylococcusaureussepsis AT canozozlem effectofgranulocytecolonystimulatingfactorinexperimentalmethicillinresistantstaphylococcusaureussepsis AT kirmacibeyhan effectofgranulocytecolonystimulatingfactorinexperimentalmethicillinresistantstaphylococcusaureussepsis AT doganaymehmet effectofgranulocytecolonystimulatingfactorinexperimentalmethicillinresistantstaphylococcusaureussepsis |